Since the interim results, Polarean has made three further announcements including the sale of a complete Xenon MRI system to the National Institutes of Health Clinical Center, a significant follow on sale to the University of Virginia and, most recently, an expansion of the Representative Agreement it signed with Ascend Imaging (Ascend) in June. Collectively, we believe the new sales secure Polarean's current revenue guidance of US$2.5m-US$3.5m for 2025 and bode well for future sales announcements now that the log jam for Polarean caused by the hiatus in US medical health funding may be breaking. The expansion of the Ascend agreement bolsters Polarean's sales penetration to a further fourteen states in the US.
